Chris Halliday, left, and Dion Bregman of Morgan, Lewis & Bockius (courtesy photos)

The $2.5 trillion CARES Act signed into law by President Donald Trump on Friday to distribute coronavirus relief seemingly has something for everyone, including even the U.S. Patent and Trademark Office. The law gives Andrei Iancu, the director of the U.S. Patent and Trademark Office, the discretion to “toll, waive, adjust, or modify” any deadline established by the Patent Act, the America Invents Act and the Trademark Act during the period of national emergency (plus an extra two months). The director would merely have to declare that the COVID-19 emergency materially affects the functioning of the office; prejudices the right of applicants, registrants or patent owners; or prevents applicants, registrants or patent owners from filing a document or a fee with the office.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]